Friday, 06 Dec 2019

You are here

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

A longitudinal health administrative data (HAD) study from British Columbia, Canada compared two cohorts of 7,743 OA patients and 23,229 non‐OA controls to examin the risk of incident CVD (primary outcome) as well as ischemic heart disease (IHD), congestive heart failure (CHF) and stroke (secondary outcomes).

OA patients had a higher risk of developing CVD compared to people without OA. The adjusted hazard ration (HR) was 1.23 (95% CI, 1.17, 1.28) and was 1.42, 1.17, and 1.14 for CHF, IHD and stroke, respectively.

Approximately 41% of the total effect of OA on increased CVD risk was mediated through NSAID.

These data show an increased risk of CVD in OA patients and is the first study to show that NSAID's substantially mediated this risk.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Warns 15 CBD Manufacturers

Today, the U.S. Food and Drug Administration issued warning letters to 15 companies for illegally selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).  This warning affirms that the FDA has not determined the many preparations of cannabidiol to be safe or effective.

Biologic Safety Guidelines from the British Society for Rheumatology

In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis. This guidance document on biologic safety covers baseline screening, monitoring, effect of co-morbidities, and when or under what circumstances biologic therapy should be interrupted.

Herpes Zoster Vaccine Update

Shingrix (GSK), the herpes zoster subunit vaccine (a two-shot series), was approved by the FDA in Fall 2018 and is currently approved for use in adults 50 years and older. Shingrix has replaced the live zoster vaccine, Zostavax (Merck) as the preferred shingles vaccine, however its use in patients with immune-mediated inflammatory diseases (IMIDs) remains a gray area.

A Focus on WOCBA (Women of Childbearing Age)

Largely because it can be difficult to do studies in pregnant women, gaps remain in the area of rheumatic disease in pregnancy. This year’s ACR highlights some important new points to consider.

Influenza Vaccine Updates And Pearls At ACR 2019

As we enter flu season it is of the utmost importance that we remember to assess our patients’ influenza vaccine status at each visit.